ArticleFrontiers in psychiatry2025
Serum HMGB1 as a diagnostic biomarker and mediator of childhood trauma in adolescent depression.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Anti-HMGB1 Antibody Therapy Ameliorates Depression Following Spinal Cord Injury in Rats by Inhibiting Ferroptosis.Journal of cellular and molecular medicine · 2026Article
- Adolescent adversity persistently induces proinflammatory HMGB1 signaling and disrupts the basal forebrain cholinergic system in female rats.Neurobiology of stress · 2026Article
- Associations of childhood trauma with clinical features and inflammatory cytokines in adolescents with first-episode and recurrent major depressive disorder.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adolescent depression is a global health challenge with increasing rates and long-term impacts on development. Current diagnostics lack objective biomarkers, relying on subjective assessments. Neuroinflammation, particularly High mobility group box 1 (HMGB1), a systemic inflammation mediator, is implicated in adult depression but not well-studied in adolescents. Childhood trauma, a risk factor for neuroinflammatory dysregulation, has been linked to increased inflammatory markers but not specifically to HMGB1. This study explores serum HMGB1 as a diagnostic biomarker for adolescent depression and its role in exacerbating symptoms through childhood trauma. Methods: 160 participants, including 80 depressive adolescents and 80 healthy controls, were enrolled. The depressive symptoms of depressive adolescents were evaluated with clinical scale. Serum HMGB1 levels were measured by enzyme-linked immunosorbent assay (ELISA). Correlation analysis, multiple linear regression, and mediation effect analysis were utilized to examine the relationship between serum HMGB1 levels and depressive symptoms severity. Results: Compared with the control group, serum HMGB1 levels (t = -18.48, Conclusion: Serum HMGB1 levels are potential markers of depression, and childhood trauma partially mediates the relationship between HMGB1 and depressive symptoms severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.